Paper42201461
High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.
Yoshino K and 10 others. Int J Clin Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer. Papers, record 42201461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42201461
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Dexamethasone | Major topic |
| Oxaliplatin | Major topic |
| Drug Hypersensitivity | Major topic |
| Humans | |
| Female | |
| Male | |
| Aged | |
| Middle Aged | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Adult | |
| Retrospective Studies | |
| Aged, 80 and over | |
| Neoplasm Metastasis | |
| Infusions, Intravenous | |
| Leucovorin | |
| Fluorouracil | |
| Organoplatinum Compounds |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32880601 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32880601 | PubMed |
| 2 | 36701137 | Rechallenge After Oxaliplatin-Induced Hypersensitivity Reactions. | JAMA Oncol | 2023 | https://conductscience.org/library/papers/36701137 | PubMed |
| 3 | 33724754 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 | https://conductscience.org/library/papers/33724754 | PubMed |
| 4 | 36252154 | Treatment of Metastatic Colorectal Cancer: ASCO Guideline. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36252154 | PubMed |
| 5 | 34102137 | First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. | Lancet | 2021 | https://conductscience.org/library/papers/34102137 | PubMed |
| 6 | 20728210 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. | Lancet | 2010 | https://conductscience.org/library/papers/20728210 | PubMed |
| 7 | 12888815 | Hypersensitivity reactions related to oxaliplatin (OHP). | Br J Cancer | 2003 | https://conductscience.org/library/papers/12888815 | PubMed |
| 8 | 8156529 | Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. | Cancer | 1994 | https://conductscience.org/library/papers/8156529 | PubMed |
| 9 | 24286446 | Immediate-type hypersensitivity drug reactions. | Br J Clin Pharmacol | 2014 | https://conductscience.org/library/papers/24286446 | PubMed |
| 10 | 22987983 | Prevention and handling of acute allergic and infusion reactions in oncology. | Ann Oncol | 2012 | https://conductscience.org/library/papers/22987983 | PubMed |
| 11 | 22855191 | Effectiveness of oxaliplatin desensitization protocols. | Clin Transl Oncol | 2013 | https://conductscience.org/library/papers/22855191 | PubMed |
| 12 | 7828281 | Hypersensitivity and cross-reactivity to cisplatin and analogues. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7828281 | PubMed |
| 13 | 31102054 | Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France. | Support Care Cancer | 2019 | https://conductscience.org/library/papers/31102054 | PubMed |
| 14 | 16421419 | OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16421419 | PubMed |
| 15 | 19739272 | Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. | Clin Colorectal Cancer | 2009 | https://conductscience.org/library/papers/19739272 | PubMed |
| 16 | 1277442 | Immediate (type I) allergic responses to platinum compounds. | Clin Allergy | 1976 | https://conductscience.org/library/papers/1277442 | PubMed |
| 17 | 25862137 | Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol. | Clin Ther | 2015 | https://conductscience.org/library/papers/25862137 | PubMed |
| 18 | 2348469 | Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. | J Natl Cancer Inst | 1990 | https://conductscience.org/library/papers/2348469 | PubMed |
| 19 | 22576054 | Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. | Cancer Immunol Immunother | 2012 | https://conductscience.org/library/papers/22576054 | PubMed |
| 20 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42201461
GET https://conductscience.org/api/papers/v1/42201461/references?page=2